Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People diagnosed with cancer over a year ago and those who were not on treatment did not have a higher risk of hospitalization or death.
CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.
Studies evaluate the impact of COVID-19 infection, treatments and vaccination in this uniquely vulnerable population.
People with blood cancers and those on chemotherapy may not respond adequately to their first two vaccine doses.
Certain types of cancer treatment can lead to inadequate immune response.
The booster is recommended for organ transplant recipients, people receiving cancer treatment and people with advanced or untreated HIV.
A study from the Leukemia & Lymphoma Society finds that antibody production varies widely across blood cancer types.
Natural immunity and vaccine responses may be weaker in people with immune suppression, so they should get their second dose promptly.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.